Related Experiment Video

Updated: May 29, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Funding mechanisms and program management at the National Heart, Lung, and Blood Institute: confronting new

Susan B Shurin1

  • 1National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA. shurinsb@nhlbi.nih.gov.

Blood
|August 27, 2011
PubMed

Insights

The National Heart, Lung, and Blood Institute (NHLBI) is managing reduced funding to sustain research and training. Actions aim to maximize support for investigator-initiated research and scientists at all career stages.

Area of Science:

  • Biomedical research funding
  • Health research management

Background:

  • National Institutes of Health (NIH) budget has declined in purchasing power over 8 years.
  • Fiscal year 2011 saw a 1% decrease in NIH appropriation, the first in 40 years.
  • The National Heart, Lung, and Blood Institute (NHLBI) faces resource limitations.

Purpose of the Study:

  • To describe NHLBI's strategies for managing reduced funding.
  • To outline measures for protecting core research and training functions.
  • To detail efforts in maximizing support for biomedical research.

Main Methods:

  • Rigorous evaluation of funding mechanisms.
  • Strategic management of clinical studies.
  • Review of set-aside programs and funding guidelines.
  • Consultation with the advisory council.

Main Results:

  • NHLBI implemented actions to mitigate the impact of resource limitations.
  • Focus on maximizing support for investigator-initiated research.
  • Efforts to maintain a balanced research portfolio.
  • Prioritization of support for established and early-stage investigators.

Conclusions:

  • NHLBI is actively managing financial constraints to support scientific advancement.
  • The Institute aims to minimize long-term impacts on research and training.
  • Strategies focus on efficient resource allocation and sustained investigator support.

More Related Videos

Air-Inflation of Murine Lungs with Vascular Perfusion-Fixation07:19

Air-Inflation of Murine Lungs with Vascular Perfusion-Fixation

Published on: February 2, 2021

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...